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ABSTRACT

In an effect to develop for more selective neuronal nicotinic acetylcholine
receptor analgesics that have less toxicity and adverse side effects relative to
epibatidine, three new classes of epibatidine analogues were synthesized and
evaluated in vitro as potential potent selective nAChR ligands. Specifically, three
analogues of epibatidine were synthesized to explore the structure-activity
relationships of epibatidine relative to neuromuscular blocking activity as well as
nAChRs. Both quaternary epibatidine analogues 2 and bis-epibatidine derivative 3
exhibited high binding affinity relative to nicotine. In addition, a new series of
2-(hydroxyalkylpyridyl)-7-azabicyclo[2.2.1]heptane derivatives were synthesized and
evaluated as potential ligands for nicotinic acetylcholine receptors. Moreover, two
rigid 2-acetoxy-7-azabicyclo[2.2.1]heptane analogues have been prepared to study the
binding conformation of acetylcholine at the active sites of the nicotinic acetylcholine
receptors.

viii

1

INTRODUCTION

Neuronal Nicotinic Acetylcholine Receptors

Acetylcholine (1) was one of the first neurotransmitters to be discovered. It is
produced by the synthetic enzyme choline acetyltransferase that uses acetyl coenzyme
A and choline as substrates for the formation of acetylcholine. Acetylcholine receptors
in the mammalian central nervous system can be divided into muscarinic 2 (mAChR)
and nicotinic 3 (nAChR) subtypes based on the ability of the natural alkaloids,
muscarine and nicotine, to mimic the effects of acetylcholine as a neurotransmitter.
Neuronal nAChRs are members of the ligand-gated ion channel superfamily that play
a key role in the signal transmission between cells at the nerve/muscle synapses.1
They are distributed both in the peripheral and central nervous systems, and growing
evidence from animal and human studies indicated the involvement of nAChRs in
high brain functions and in important neurodegenerative pathologies.2 The nAChRs
also are the body’s primary targets of nicotine from tobacco products.
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Over the last decade, neuronal nAChRs have been the target of medicinal
chemists. There is evidence that a deficit of nAChRs is implicated in the
symptomatology of Alzheimer’s disease, and nicotine itself has been shown to be
beneficial in the symptomatic treatment of Alzheimer’s disease and to exert
neuroprotective effects in several in vivo models.4 Preclinical research has
demonstrated the therapeutic potential of some nAChR agonists in the treatment of
the Parkinson’s disease as well.3 Implications of nAChRs in a number of other
relevant physiological and pathological processes, like appetite, schizophrenia,
epilepsy, depression and analgesia, have been also suggested.4, 5
A number of natural products have been disclosed to selectively activate
nAChR subtypes, and this has prompted a search for other subtype-selective
non-natural nAChR ligands as potential therapeutic agents. The interaction of nicotine
with nAChRs is the key step in the process that leads to nicotine addiction. Nicotine
(3) is an alkaloid contained in the leaves of several species of plants. Defects in or
loss of acetylcholine signaling would be expected given the wide variety of important
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roles of the receptor in normal brain and body function. The nAChRs also are the
body’s primary targets of nicotine from tobacco products. It is believed that selective
nAChRs agonists and antagonists could prove to be of great therapeutic benefit for the
treatment of a variety of disease states and disorders. Unfortunately, side effects such
as cardiovascular and gastrointestinal dysfunction, addiction, neuromuscular effects
and seizures have limited the use of nAChR agents in drug therapy. Therefore, the
search for potent and selective nAChR agents is an extremely important endeavor that
will provide pharmacological tools for the study of nAChR function as well as to
provide therapeutic agents and medications for the treatment of a variety of
neurological disease states.

Nicotinic Acetylcholine Receptor Structure and Subtypes

The structure of peripheral nAChRs is isolated from the electric organ of the
Torpedo ray (Torpedo California) have has been well characterized. It has been shown
to possess five transmembrane protein subunits which assemble to form the ion
channel (Figure 1).6 Each subunit consists of four transmembrane α-helical domains
(M1-M4). The inside wall of the channel is made up by five α-helices coming from the
M2 domains of each five subunits. Various subunits (α, β, γ, δ and ε) have been
identified in the nAChRs of the mammalian skeletal muscle that have a pentameric
structure constituted by two α-subunits and one each of β, δ, and γ (ε).

4

Figure 1. Schematic drawing for the nAChR channel which consists of five subunits:
α, α, β, γ, and δ. (a) Side view. (b) Top view. (c) The transmembrane topology for each
subunit. Five M2 segments (one from each subunit) form the channel pore as shown in
(b). Activation of nAChR channel requires binding of two acetylcholine molecules, one on
each α subunit.6

However, neuronal nAChRs have not been as well characterized, primarily
due to the structural diversity of this class of receptors. In general, neuronal nAChRs
are also thought to possess a pentameric structure consisting of a combination of nine
known α-subunits (α1-α9) with three β-subunits (β2-β4). In addition, functioning
homogenous receptors composed of either α7, α8 or α9 subunits have been expressed
in oocytes.7-9 The expressed receptors exhibit a diverse range of pharmacological
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activity and function. However, researchers have been not been able to unequivocally
correlate the function of expressed receptors with native receptors.
It is believed that the α4β2 subtype (two α4 units and three β2 units) nAChR
is the predominant neuronal nicotinic receptor subtype in the mammalian CNS.10 This
subtype binds (-)-nicotine (3) with high affinity (KD = 0.5-5 nM) and is distributed
throughout the brain, albeit the distribution of the α4β2 subtype in specific regions of
the brain is species dependent. The function of the α4β2 nAChR subtype is not
clearly understood at this time, although it is believed to be associated with cognitive
function.11 A unique feature of the α4β2 nAChR subtype is that it is up-regulated by
physiologically relevant concentrations of nicotine. This up-regulation was evident in
the post-mortem brains of cigarette smokers in which the number of [3H]-(-)-nicotine
binding sites were significantly greater than in the brains of non-smokers.12 Other
nAChR subtypes are also up-regulated by nicotine; however, these subtypes require
exceedingly large doses of nicotine for up-regulation.
A second nAChR subtype present in the brain has been suggested to be the
homogenous α7 nAChRs composed of five α7 units.13-15 This class of nAChRs has
been shown to be distinctly different form the α4β2 subtype in that it binds
α-bungarotoxin [α-Bgt is a 75 amino acid protein isolated from snake venom
(Bungarus multicinctus)] with high affinity (KD = 0.65-1.7 nM), while nicotine
exhibits only micromolar affinity for the α7 nAChR subtype.13 The concentration of
the α7 subtype nAChR in the brain is similar to that of the α4β2 subtype but the
distribution is different and species dependent. The function of the α7 is also not
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well understood at this time. However, it is thought that this class of receptors may be
associated with learning and memory processes as well as neuroprotection.16-18
It is important to note, that although a number of compounds have been
prepared and characterized as either α4β2 subtype or α7 subtype selective ligands,
within a ligand class (e.g. derivatives of nicotine, derivatives of epibatidine) there has
been no report of two or more derivatives in which one is α4β2 subtype selective and
the other is α7 subtype selective. Rather, the currently available structure-activity
relationship data suggests that structural modification of subtype selective ligands
results in binding affinity that is affected similarly and proportionally at all nAChR
subtypes.
Table 1 summarizes the various nicotinic acetylcholine receptor subtypes
discussed, their subunit makeup and location, and perceived primary function.

This

is only a partial list of the subtypes found in mammals, but describes the subtypes that
are most relevant to our research.

Table 1. Nicotinic Acetylcholine Receptor Subtypes

Classification

Subunits

Location

Neuronal (CNS)

α4β2

CNS

α7

CNS

Neuronal (Ganglionic)

α7

PNS

Muscular

α1β1δγ

Neuromuscular
Junction

Proposed Function
Memory and learning,
neurotransmitter release, pain
propagation, role in addiction
Cognitive functions,
neuroprotection
Cellular functions and
regulation
Skeletal muscle contractions
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Inhibition Constants and Effective Concentrations
Compounds are measured for their binding affinity for the nicotine receptor

by determining the concentration at which the compound displaces (or inhibits) 50%
of a radiolabeled ligand with known binding affinity. For example, [H3]nicotine or
[3H]cytisine can be used as the standard to measure binding affinity at the nAChR.
The concentration of prepared ligand required for the response is reported in molar
units as an IC50 value-the inhibition concentration. The smaller the value of the IC50 is,
the stronger the affinity of the displacing drug for the receptor would be. The
usefulness of this value is limited due to variances in technique and tissue samples
between labs. Cheng and Prusoff derived an equation (Equation 1) that incorporates
the concentration of the ligand tested [L] and the dissociation constant (Kd) of the
standard compound from the receptor.19 The smaller the value of Kd, the greater the
affinity of the ligand for the receptor. This value is also reported in molar units as an
inhibition constant (Ki).

Inhibition constants are more useful for comparison

between labs.

Ki =

IC50
[ L] K d + 1

(Eq 1)

Another measurement used to determine the potency of a ligand at a receptor
is the effective concentration (EC50). The EC50 of a compound is the molar
concentration that produces half the maximum biological response observed when
acetylcholine, the endogenous neurotransmitter, binds to a receptor. A low EC50 value
will indicate a potent compound.
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Epibatidine

In 1974, John Daly and his coworkers at the National Institute of Health
first collected a trace alkaloid from skin extracts of the Ecuadorian poison dart frog
(Epiedobates tricolor) in the Pacific highlands of Ecuador. However, too little of the
compound was isolated to make a structural determination because of lack of the
sensitive and sophisticated instruments and methods. The remaining sample was kept
in storage for years until 1992, the structure of the novel alkaloid Epibatidine (4) [(1R,
2R, 4S) exo-2- (2-chloro-5-pyridinyl)-7-azabicyclo[2.2.1]heptane] was finally
determined and shown to be a potent analgesic.19 The structure of epibatidine was
found to be a new class of alkaloids possessing a 7-azabicyclo[2.2.1]heptane
(7-azanorborane) structure, with a exo-oriented 5-(2-chloropyridyl) substituent. The
structure of epibatidine (4) closely resembles that of nicotine (3). Both contain a
pyridine ring; both contain a basic nitrogen linked to the pyridine ring by one or two
carbons; both basic nitrogen atoms are part of a five-membered ring (in epibatidine,
the five membered ring is part of the 7-azabicycloheptane structure). The structural
similarity to nicotine suggested that epibatidine would have activity at nicotinic
receptors. Indeed, epibatidine along with its singular structure, contributes to its great
appeal for

the studies by the scientific community.20 Epibatidine was found to

exhibit potent analgesic effects (200 times more potent than morphine) that were not
mediated through opioid receptors.19, 21-22 This is clearly established by the fact that
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epibatidine was not blocked by administration of the potent opiate antagonist
naloxone. Further studies demonstrated that epibatidine possessed high affinity for
neuronal and peripheral nAChRs and was 300 times more potent than (-)-nicotine.23
Although the analgesic effects of nicotine have been known for more than two
decades, the discovery of epibatidine and its exceptionally potent analgesic activity
had prompted an intensive study of the pharmacological activity of this unique
alkaloid and has renewed the search for non-narcotic nAChR mediated analgesic
agents.

Epibatidine,

4

Epibatidine In Vitro Neuronal nAChR Pharmacology

In vitro binding studies, employing radiolabeled competition assays in rat
brain, have shown that epibatidine displaced α4β2 subtype selective ligands
[3H](-)-nicotine (3) and [3H](-)-cytisine (5) with Ki’s of 55 pM22 and 43 pM23,
respectively, thus making epibatidine the most potent nAChR ligand known to date.
[3H]Cytisine (5) binds with high affinity to α4β2 subtype of nAChRs, the major
subtype in rodent brain (>90% of (-)-nicotine binding site).24 However, in binding
studies with [3H] α-Bgt, epibatidine was not nearly so potent, having a Ki of 230 nM,
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albeit, epibatidine was still 20-fold more potent than (-)-nicotine in this paradigm.23
This suggests that epibatidine is more selective for the α4β2 nAChR subtype over the
α7 nAChR subtype. It has been shown that epibatidine labels more than one binding
site in rat brain, human brain and mouse brain.25 The distribution of [3H]epibatidine
sites in rat brain closely matches that of [3H]cytisine, with a few exceptions.26 One of
the sites labeled by epibatidine appears to be cytisine-insensitive, and these sites
appear to be located primarily in diencephalic and mesencephalic brain regions.27 The
(+) and (-)-enantiomers of epibatidine displace [3H]nicotine binding with similar
affinities and display similar analgesic efficacies.22

(-)-Cytisine,

5

Epibatidine Stimulates Dopamine and Norepinephrine Release
Epibatidine stimulated [3H]dopamine release with an EC50 of 0.4 ± 0.1 nM,
compared to (-)nicotine, which had an EC50 of 60 ± 12 nM.23 In addition, epibatidine
was more efficacious than nicotine at stimulating dopamine release. The stimulated
release of dopamine by epibatidine was blocked by both the competitive nAChR
antagonist DHβE and the non-competitive nAChR antagonist mecamylamine(6).23 It
has been suggested that the subunit involved in dopamine release is the α4β2
subunit,28 however in mouse striatal synaptosomes the α3 subunit has also been
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implicated.29, 30 In mice lacking the β2 subunit of nAChRs, epibatidine binding was
almost completely wiped out, although there was a small amount of residual binding
in a few select brain regions including the lateral medial habenula and the dorsal
interpeduncular nucleus.31 Epibatidine stimulated release of norepinephrine in the
dentate gyrus region of the hippocampus with an EC50 of 19.6 nM (compared to
nicotine with an EC50 of 34 nM).32 This value is considerably higher than that seen for
dopamine release22 suggesting the potential involvement of a different receptor
subtype. In fact, it is thought that epibatidine stimulated norepinephrine release occurs
via the α3β2 subtype of receptor,32 thus, by measuring the effects of epibatidine
analogues on release of both dopamine and norepinephrine, it may be possible to
determine differential efficacies and potencies at these two nAChR subtypes.

Mecamylamine, 6

Hexamethonium, 7

Epibatidine In Vivo Neuronal Nicotinic Acetylcholine Receptors Pharmacology

In vivo, epibatidine was found to possess potent analgesic activity in rats.
From tail-flick and hotplate assays, the analgesic effects of epibatidine were found to
be 200-fold more potent than morphine.19-21 However, the analgesic effects elicited by
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epibatidine were not blocked by the opiate antagonist naloxone which suggests a
non-opioid mechanism of action. The analgesic effects of epibatidine were blocked by
the neuronal nAChR antagonist mecamylamine (6).20 Alternatively, the peripheral
nAChR antagonist hexamethonium methiodide (7), which is incapable of penetrating
the blood-brain-barrier, had no effect on the analgesic effects of epibatidine.21 This
suggests that the analgesia elicited by epibatidine is mediated through occupation of
neuronal nAChRs. However, it is uncertain whether the α4β2 nAChR subtype, the α7
nAChR subtype or some other nAChR subtype mediated the analgesic activity.22.23 In
addition, epibatidine was found to lower body temperature in mice and decrease
locomotor activity. These effects were also antagonized by mecamylamine (6) and not
affected by hexamethonium (7). Although the analgesic effects of nicotine have been
known for more than two decades, the potency of epibatidine is far greater than that
observed for any other nAChR ligand. However, it is unlikely that epibatidine itself
will ever be developed as an analgesic agent since a therapeutic dosage closely
approaches levels which induce severe hypertension, convulsions, respiratory
depression and death.22, 34

Nicotinic Acetylcholine Receptors Pharmacophore Models

The term pharmacophore was originally described by Paul Ehrilich more
than 100 years ago and it is defined as the three-dimensional arrangement of atoms
or groups of atoms that are responsible for the biological activity of a drug molecule.
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Specifically, a pharmacophore for the nAChR should possess the physiochemical
properties necessary to stimulate activity at the receptor. During the last fifty years,
several studies have been performed with the aim to define nicotinic cholinergic
pharmacophores. Due to the small number of compounds available to investigators
and the lack of homogeneity in tissue/receptor preparations used to evaluate activity,
pharmacophore models from the early research were of limited significance.
Among the most important studies, around 1970, based on examination of a
series of agents using Dreiding and CPK space-filling models, Beers and Reich found
nicotinic agents (both agonist and antagonist activity) must be characterized by two
common structural features. They are: (1) a couloumbic interaction involving an
alkylammonium moiety, and (2) a hydrogen bond that depends upon the presence of
an acceptor moiety in the nicotinic agent at a distance of 5.9 Å away from the center
of the positive charge ( Figure 2a ). 35 Sixteen years later, Sheridan and co-workers 36
developed a pharmacophore model based on three features; a basic nitrogen atom
(corresponding to the pyrrolidine nitrogen in nicotine), a hydrogen bonding acceptor
(e.g., the pyridine nitrogen of nicotine or the carbonyl oxygen atom of cytisine), and a
third point representing the centroid of the pyridine ring of nicotine or the carbonyl
carbon atom of cytisine or other agonists. They also noted a distance of 1.2 Å between
the H-bond acceptor and a third atom that resides above the plane of the internitrogen
space (Figure 2b).
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Figure 2. Comparison of the Beers and Reich Pharmacophore with the Sheridan model
( a ) The Beers and Reich pharmacophore model: Distance d represents the distance
between the onium site and the van der Waals surface of a hydrogen bond acceptor
atom; optimal d = 5.9 Å. ( b ) a representation of the pharmacophore produced by
Sheridan et al. : Idealized distances are A-B: 4.8 Å, B-C: 1.2 Å, and C-A: 4.0 Å.

(a) Beers and Reich

(b) Sheridan

Based on X-ray crystallographic data of ligands, Barlow and Johnson
(1989)37 suggested the agonist activity to require a charged nitrogen (i.e., an onium
site) and a planar area on the receptor recognizing an aromatic ring or a double bond
through hydrophobic or p-p interactions. Glennon et al.

38

performed QSAR studies

on a series of agents structurally related to nicotine (3) and epibatidine (4), and found
their affinities to parabolically correlate with the respective N-N distances (optimal
distance 5.1-5.5 Å). This model was, however, too simplistic to rationalize the
agonism of other compounds, such as aminoethoxypyridine derivatives and
unsaturated aminoalkylpyridines

39

, that displayed an affinity higher than that

expected from the calculated internitrogen distances. A relevant contribution has been
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given by Livingstone et al. in 1996.40 Seven semirigid agonist molecules were
analyzed through a comparative analysis of the gnomonic projections of surface
molecular properties. Three significant features defined the pharmacophore: (i) a
cationic head, (ii) a ring centroid of a pyridine ring or the carbon atom of a carbonyl
group, and (iii) a dummy atom indicating the location on the receptor of an atom
likely making an H-bond with the pyridyl nitrogen or the carbonyl oxygen. A
lipophilic region, close to the positions 3’ and 4’ of the pyrrolidine ring of nicotine,
had been considered as an important modulator of the agonistic activity, but it had not
been used in the derivation of the pharmacophore model.

Structure-Activity Relationships at Nicotinic Acetylcholine Receptors

Compounds with similar structures often tend to have similar
pharmacological activity. However, they usually exhibit differences in potency and
unwanted side effects and in some cases different activities. These structurally related
differences are commonly referred to as structure-activity relationships. A study of the
structure-activity relationships of a lead compound and its analogues can be used to
determine the parts of the structure of the lead compound that are responsible for its
biological activity, that is, its pharmacophore and also its unwanted side effects. This
information is subsequently used to develop a new drug that has increased activity,
and a different activity from an existing drug, fewer unwanted side effects and
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improved ease of administration to the patient. The structure-activity relationships of
a compound or a class of compounds are usually determined by making minor
changes to the structure of the lead compound and assessing the effects of the
structural change on biological activity. Traditional structure-activity relationships
investigations are carried out by making large numbers of analogues of the lead and
testing them for biological activity. Over the years after discovering epibatidine,
numerous analogues have been investigated. Such hybrids should take into account
the assets of known drugs such as favorable distances between atoms, functional
group moieties, and structural similarities resulting in potency with decreased toxicity.

Structure-Activity Relationships of Epibatidine at Nicotinic Acetylcholine Receptors
In light of the high potency and extraordinary analgesic effects of
epibatidine, several studies of the structure-activity relationship of this novel alkaloid
have been reported. It has been shown that natural (-)-epibatidine and unnatural
(+)-epibatidine are equipotent in [3H]nicotine labeled rat brain.20 However, the
C2-epimer 8 exhibited diminished binding affinity.41 N-Methylation of (-)- and
(+)-epibatidine (9) resulted in slightly reduced binding affinity in rat brain as well as a
small enantioselective differential in binding affinity such that the natural analogue
was three-fold more potent than the unnatural analogue.20, 21
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8

9

Another important structure-activity relationship study for epibatidine was a
series of substituent derivatives on the pyridyl ring. It has been found that removal of
the chloro substituent (10a) did not affect binding potency. Likewise the replacement
of the chloro substituent with methyl, fluoro or iodo (10b-d) did not affect the binding
potency relative to epibatidine.19-21, 42 The amino moiety 10f was found to exhibit
decreased binding affinity with respect to epibatidine, but maintained potency
comparable to nicotine. The 2-position was not tolerant of a hydroxy group 10g, a
dimethyl amino group 10h, and a triflate 10i as seen by lower binding affinities for
these analogues.7

There are also a few examples reported in the literature where the pyridine
ring of epibatidine has been replaced by an alternative heterocyclic ring.
(±)-Epiboxidine (11) was reported to exhibit potent binding affinity in [3H]nicotine
labeled rat brain but was 10-fold less potent than (-)-epibatidne.43 The analgesic

18

activity of 11 was also diminished 10-fold relative to epibatidine in rat hot-plat assays,
but 11 was 10-fold less lethal in mice43. The N-methyl analogue 12 exhibited similar
binding affinity and analgesic efficacy to 11. The oxadiaxolyl derivative 13 was
shown to be 30-fold less potent than ( ± )-epibatidine.44

Several bicyclic analogues and homologues of epibatidine have been
reported to exhibit binding affinity at nAChRs and elicit analgesic activity. The
isomeric 2-azabicyclo[2.2.1]heptane analogues of epibatidine 14 and 15 were found to
be similar in potency to nicotine, but were about 50% less efficacious in dopamine
release experiments.45 The 2-azabicyclo[3.2.1]octane homologue 16 was shown to
possess binding affinity similar to nicotine and the 8-azabicyclo[3.2.1]octane
homologue 17 was reported to exhibit analgesic activity equal to epibatidine at a dose
that was only 4-fold greater.46
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Structure-Activity Relationships of Pyridyl Ethers

Probably the most significant development in the field of nAChR research
since the discovery of epibatidine has been the discovery of the 3-pyridyl ethers as a
potent nAChR ligand class. In 1996, Holladay and coworkers synthesized a series of
methylated and demethylated pyrrolidines and azetidines with 3-pyridyl ether
functional groups. The pyrrolidine derivatives A-84543 (18) and ABT-098 (19)
exhibited potent binding affinity at [3H]nicotine labeled binding sites and are selective
for α4β2 nAChRs. The azetidine analogue A-85380 (20) was reported to exhibit
extremely potent binding affinity (Ki = 50 pM), similar to that of epibatidine and also
demonstrated selectively for the α4β2 nAChRs.47 The R-2-chloro analogue ABT-594
(21) has a very low affinity for the nicotine receptors in the neuromuscular junction
which cause the paralysis effect, but it has a high affinity for the nicotine receptors in
the central nervous system which regulate pain perception. Moreover, ABT-594 has
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been described as producing orally effective analgesia of similar potency to
(±)-epibatidine.48 The R-isomer 21 was found to be only slightly more potent than its
enantiomer. More significantly ABT-594 (21) is currently being studied as a potential
therapeutic agent for the control of pain.49, 50

Recently in our labs, 2-substituted rigid 7-azabicyclo[2.2.1]heptanes 22-24
were synthesized.51 All compounds showed a lower binding affinity than epibatidine
and nicotine, with the endo 22a-c exhibiting low to moderate micromolar
concentrations as well as the dechlorinated exo compounds 23a, 23c.

The exo

6-chloropyridine 23b offered the best binding, in the submicromolar range, and
though still too low for potent therapeutic use, the structure-activity relationships of
the ethers were consistent with those of epibatidine and its analogues. The 2-pyridyl
derivatives 22c, 23c and the amide analog 24 did, however, display comparable
potency to the 3-pyridyl homologues, which had not been seen in other series. With
the

ether

linkage

in

the

2-position

of

the

bicyclic

system,

the
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7-azabicyclo[2.2.1]heptane ring does not substitute for the azetidine ring as
recognized by the α4β2 receptor.

Neuromuscular Blocking Agents

The clinical value of an ultra-short-acting nondepolarizing neuromuscular
blocking drugs (NDNMBDs) via continuous infusion in the intensive care unit has
long been recognized and is gaining in popularity. Savarese and Kitz termed such a
compound an “ideal” muscle relaxant.52 Since then, several new NDNMBDs have
been developed; these drugs vary in degree of onset and duration of action, as well as
routes of elimination.53 Examination of the chemical structure of these relaxants
reveals that they are either benzylisoquinolinium or aminosteroid compounds.
Recently, Gyermek and coworkers have explored the role of ester groups in the
neuromuscular blocking property of various quaternary ammonium tropinesters.53, 54
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Among them, G-1-64 (25) exhibited favorable neuromuscular blocking characteristics
and modest side effects. Since epibatidine (4) exhibits potent analgesic effect and
possesses high affinity for neuronal and peripheral nAChRs, structurally similar
epibatidine derivatives may have clinical potential.

Total Synthesis of Epibatidine

For nearly a decade now, chemical research groups all over the world have
been captivated by epibatidine since the elucidation of the structure of epibatidine and
its analgesic activity was published in 1992. The azabicycloheptane system of
epibatidine is not common among natural products. Synthetic chemists Corey 55, Shen
56

, Broka 57, and Clayton and Regan

58

were among the first to report total syntheses
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of epibatidine. Many other synthetic routes were later reported (See references 59-61
for reviews). Based on the strategy of forming the azabicyclic ring system, most
synthetic approaches can be classified into three categories: (1) intramolecular
nucleophilic displacement reaction, (2) Cycloaddition reaction and (3) miscellaneous
reactions like ring contraction of the tropinone skeleton via a Favorskii rearrangement
and radical cyclization.
1. Intramolecular Nucleophilic Displacement Reaction 62-68
Intramolecular nucleophilic 1,4-substitution of a trans-substituted cyclohexane
derivative to construct the 7-azabicyclo[2.2.1]heptane ring system might be the most
popular approach in total synthesis of epibatidine and its analogues. Table 2
summarizes the various precursors for epibatidine and its analogues from the recent
literature.
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Table 2. Summary of Previous Total Synthesis of Epibatidine

2. Cycloaddition Reaction
One type of the cycloaddition reaction that has been successful is [4+2]
Diels-Alder cycloaddition which employs an N-protected pyrrole as the diene
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and a substituted acetylene derivative as the dienophile to prepare the
7-azabicyclo[2.2.1]heptane framework of epibatidine (Scheme 1). Shen and
Huang first reported a Diels-Alder based synthesis of epibatidine using the
N-pyrrole and phenyl sulfonyl 6-chloro-3-pyridyl acetylene.56 Our group
reported an efficient total synthesis of epibatidine by using N-Boc pyrrole and
methyl 3-bromopropiolate in [4+2] cycloaddition.69 Our lab also employed
allenes in the Diels-Alder reaction to synthesize the important intermediate
N-protected 7-azabicyclo[2.2.1] heptan-2-one.70

Scheme 1

Another strategy to assemble the epibatidine skeleton was [3+2]
dipolar Cycloaddition reaction. It was reported by Pandey and coworkers71
(Scheme 2) that the [3+2] cycloaddition of a nonstabilized azomethine ylide
with cis-ethyl-3-(6-chloro-3-pyridyl)-2-propenoate gave the cycloadduct
possessing the 6-chloro-3-pyridyl ring with the desired exo-stereochemistry.

Scheme 2
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3. Miscellaneous Reactions
One interesting strategy for synthesis of epibatidine is the ring
contraction via Favorskii rearrangement (Scheme 3) reported by Bai and
coworkers.48 A N-protected tropane was treated with cupric bromide to give
the monobromide, which was subjected to the Favorskii rearrangement with
sodium methoxide to afford the contracted bicyclic ester in 56%. The
following reductive palladium-catalyzed coupling reaction and radical
decarboxylation afforded the N-protected azabicyclohexane, which was
subsequent by deprotected reaction furnish epibatidine in 83% yield.

Scheme 3
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Specific Aims and Design Strategy

As discussed earlier, the natural product epibatidine (4) is one of the most
potent nicotinic acetylcholine receptors ligands to date. Its exceptionally potent
analgesic activity has prompted an intense study of this unique alkaloid and renewed
interest in the search of non-narcotinic nAChR mediated analgesic agents. However,
the therapeutic potential of epibatidine is limited due to its acute toxicity at a dose
only slightly higher than its effective analgesic dose.
In an effort to develop nicotine acetylcholine receptor selective agonists
and antagonists as potential therapeutic agents for nicotine addiction and other central
nervous system disorders mediated by the nicotinic acetylcholine receptors, novel
analogues of the epibatidine will be synthesized and evaluated in vitro as potential
nicotinic acetylcholine receptors ligands

Epibatidine and Quaternary Ammonium Salt Derivatives

Recently, Gyermek and coworkers reported a bisquaternary ammonium
tropine ester (G-1-64, 25) 53 as a new class of neuromuscular blocking (NMB) agents
with modest side effects. The exceptionally potent activity of epibatidine has
prompted an investigation of the bis-epibatidine ammonium salt derivatives. To this
end, the efficient synthesis of (±)-epibatidine (4) as well as its quaternary ammonium
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salt and bis-epibatidine derivatives (26-28) will be investigated to provide useful
quantities of these rare compounds for study.

4

26

27

28

Pyridyl ether derivatives
Based on the high potency and extraordinary analgesic effects of
epibatidine and ABT-594, it is of interest to study hybrids of these compounds. To this
end, a series of pyridyl ether derivatives 29a-c have been envisaged to explore the
structure-activity relationships of epibatidine related compounds. The derivatives
were designed to be hybrid structures of epibatidine and ABT-594. In this series, the
effect of the position of the nitrogen atom in the pyridyl ring for molecular
recognition at the receptor site will also be evaluated.

29a-c
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Rigid Acetylcholine Analogues
The nicotinic acetylcholine receptors are responsible for recognition and
binding of the neurotransmitter, acetylcholine (1). Acetylcholine binds to the receptor
activating the ligand gated ion channel and stimulating the central and
parasympathetic nervous system. Acetylcholine is flexible molecule with many
possible conformations. The topography of the ion-channel of the acetylcholine
receptor is not fully known. Likewise, the binding conformation of acetylcholine is
unknown. By constructing several rigid conformations of acetylcholine and its
derivatives, a better understanding of its spatial geometry within the receptor, and
ultimately the three-dimensional receptor structure can be achieved. To this end, a
series of rigid 2-acetoxy-7-azabicycloheptane analogues have been prepared. They
will be used to study the binding conformation of acetylcholine at the active site of
the nAChRs.
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RESULTS AND DISCUSSION

Total Synthesis of Epibatidine and Quaternary Ammonium Salt Derivatives

Chemistry
A variety of synthetic approaches to epibatidine have been reported based
primarily on three different methods for the construction of the novel azabicyclic
system as discussed earily.55-67 Among those versatile methods, the condensation of
N-protected azabicyclic ketone with pyridinyl substituent has been shown to be one of
the most straightforward methods for the construction of the basic skeleton of
epibatidine. The synthetic approach for the total synthesis of epibatidine followed
the previous work established in our laboratories. 70 However, the yields of some key
steps were significantly improved.
The total synthesis of epibatidine was developed around the [4+2]
cycloaddition reaction of N-substituted-pyrrole with an appropriate substituted
dienophile to provide the 7-azabicyclo[2.2.1]heptane skeleton.70 As illustrated in
Scheme 4, 73-75,70

the substituted dienophile was prepared from propiolic acid 30,

which was first esterified (31),73 followed by bromination with N-bromosuccinimide
(NBS) to furnish 32 in 74% yield.74 N-Pyrrole (33) is a poor diene for the [4+2]
cycloaddition reaction and usually it can be activated by the addition of
alkyloxycarbonyl group.75 It was found in the literature that the yield of this

31

protection procedure is 81% after 15 h. However it was found that if the reaction
time (33 to 34) was increased to 2 days, the yield is almost quantitative (>98%).
With both starting materials in hand, heating 28 with 5 equivalents of 26
at 85-90 °C for 30 h gave the expected cycloaddition adduct 29 in 67% yield. As
this is step is very early in the total synthesis of epibatidine, the yield of the
cycloaddition reaction is important to the overall yield. The highest previous yield
of this step was only 60%. After many attempts to optimize this reaction, it was
discovered that temperature was important to this cycloaddition reaction.

The

reaction temperature should be maintained between 85-90 °C. This improved the
yield of this step from 60% to consistent yields approaching 70%.
Scheme 4

As illustrated in Scheme 5, treatment of 35 with diethylamine, followed by
hydrolysis with 10% HCl, afforded the desired β-keto ester 36 in 86% yield as a
mixture of isomers (endo/exo, 7:1). Initially, yields for this reaction were lower than
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yields reported in the literature. It was found that 10% HCl should be added slowly
but not dropwise. In addition, the reaction time was decreased to 3.5 h compared to 4
h previous reported in the literature. This gave consistent yields of almost 90%.
Hydrogenation of the carbon-carbon double bond of 36 with 10% Pd/C (H2, 1 atm)
furnished 37 as a mixture of isomers (endo/exo, 3:2) in quantitative yield. The

β-keto ester 37 was then decarboxylated followed by re-introduction of the Boc
protecting group to provide the desired ketone 38 in 84% yield (Scheme 5).70 The
total yield of both the decarboxylation and Boc-protection reactions was improved
from 77% to 84% by complete removal of residual water via azeotropic distillation
with ethanol and then dried thoroughly under vacuum.
Scheme 5

It is noteworthy that the 7-azabicyclo[2.2.1]heptan-2-one 38 is of potential
value for the synthesis of epibatidine analogues as it contains the basic epibatidine
skeleton. The ketone 38 could be obtained in 7 steps from commercially available
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starting materials in 21% overall yield. This was a significant improvement from
previous reports as well as providing multigram quantities for further transformations.
The preparation of the pyridine substituents has long been known but was
prepared by an improved procedure from the recent literature76 in two steps from
2-aminopyridine 33 (Scheme 6). Direct iodination of 39 in the presence of periodic
acid gave 2-amino-5-iodopyridine 40 in 60% yield.76 Diazonium salt formation in
concentrated hydrochloric acid then afforded 2-chloro-5-iodopyridine 41 in 63%
yield.
Scheme 6

Treatment of ketone 38 with 5-lithio-2-chloropyridine, which was generated
by lithiation of 2-chloro-5-iodopyridine 41 with n-butyllithium at –78 °C under
nitrogen, afforded the tertiary alcohol 42 in 92% yield as a single diastereoismer
(Scheme 7).
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Scheme 7

This step was improved from 88% to 92%. Due to the sensitivity of n-BuLi
to water and air, this reaction required several considerations. In this reaction, even a
trace of water can influence the yield significantly. First, all glassware was flame
dried. Secondly, the amount of n-BuLi was increased slightly from 1.05 equivalent to
1.10 equivalent. Thirdly, the time of the exchange reaction (n-BuLi reacting with
2-chloro-5-iodopyridine to make 2-chloro-5-lithiumpyridine) was increased from 30
min to 45 min to ensure that the exchange reaction was complete.
Treatment of alcohol 42 with methyl oxalyl chloride afforded the
corresponding methyl oxalyl ester which, without purification, was subjected to
radical deoxygenation with tributyltinhydride (Bu3SnH) in the presence of
2,2’-azobisisobutyronitrile (AIBN). This afforded the deoxygenated product
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stereoselectively as the endo-isomer 43 in 94% yield (Scheme 7). Again, the yield of
this step was improved from 88% to 94%. This improvement was due to freshly
recrystallizing the initiator AIBN just before use. Epimerization of 43 using potassium
tert-butoxide in refluxing tert-butyl alcohol afforded the desired exo-isomer 44 in
50% yield (Scheme 7).

The yields of this step were substantially lower if the

reagents (even t-BuOH) were not dry. Deprotection of the N-Boc-protected
exo-isomer 44 using trifluoroacetic acid in CH2Cl2 at room temperature furnished
(±)-epibatidine (4) as a white solid in almost quantitative yield (98%) (Scheme 7).70
As shown in Table 3, the yields of some key steps for the total synthesis of
epibatidine have been significantly improved. The overall yield resulting from the
improved steps was increased to 48%.
Table 3. Summary of the Yields of the Improved Steps

Reaction
Scheme
Literature
Yields
Improved
Yields

Scheme 4 Scheme 4 Scheme 5 Scheme 7 Scheme 7 Overall
34
35
38
42
43
81%

60%

77%

88%

88%

29%

99%

67%

84%

92%

94%

48%

Once epibatidine (4) had been generated successfully, the syntheses of
quaternary ammonium salts were carried out. For the N,N’-dimethyl epibatidinium
iodide (26), several methods were attempted. Initial attempts to provide 26 in one step
failed due to difficulty in isolation and purification of the quaternary salt. The studies
were then focused on the preparation of 26 in two steps. The first step was to make
the N-methyl tertiary amine. Initial attempts to reduce the N-Boc precursor 44 to
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N-methyl tertiary amine also failed due to decomposition of the epibatidine ring
system. Alternatively, the direct methylation from epibatidine worked well. After
trying numerous conditions for the reductive N-methylation, as illustrated in Scheme
8, epibatidine (4) was methylated using 37% aqueous formaldehyde to provide

N-methyl epibatidine 45 in 94% yield.77 Subsequently, treatment of 45 with 25
equivalents of iodomethane for 3 h afforded the final salt 36 in 83% yield.
Scheme 8

The bis-ammonium salts were prepared in two steps. Epibatidine was treated
with 1, 10-diiododecane for 10 d to provide bis-tertiary eqibatidine 46 in 71% yield.
Treatment of 46 with HCl gave the final expected salt N,N’-decamethylene
bisepibatidinium dihydrochloride 27 in 93% yield (Scheme 7). It was hoped that
treatment

of

46

with

methyliodide

in

absolute

ethanol

would

provide

N,N’-decamethylene bisepibatidinium dimethyliodide 28. Since compound 28 has
conformation isomers due to the ten-carbon long chain, a very complex 1H NMR was
obtained. After purification of methyliodide by passing it through a pipet of
anhydrous potassium carbonate. The compound 28 was obtained in 73% yield as a

37

brown solid.
Scheme 9

Overall, the novel NMB agents with epibatidinum substituents have been
successfully synthesized. The biological activity of desired pure compounds 26-27
have been evaluated at nAChRs.

Biological Testing
The in vitro binding affinities (Ki) of the 7-azabicyclo[2.2.1]heptane
quaternary derivatives 26-27 summarized in Table 6, were measured by inhibition of
[3H]cytisine binding in homogenates of rat brain tissue. There are a variety of
nAChRs subtypes that exist in the central nervous system; however, the α4β2 subtype
is the predominant nAChR in rat striatum tissue. Therefore, the binding affinities (Ki)
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reported in Table 6 correspond to the α4β2-subtype affinity of epibatidine and related
compounds.
As shown in Table 4, both epibatidium quaternary methylioidide salt 26 and
bis-epibatidine hydrochloride salt 27 exhibited equipotent binding affinity with
(-)-cytisine and about twenty-fold more potent than unnatural (+)-nicotine. Though
they exhibited lower binding affinity when compared to (±)-epibatidine. This result
is still very exciting since it gives a new class of novel quaternary compounds that
exhibit high affinity binding nAChRs. Between these two compounds, the long chain
epibatidium hydrogen chloride 27 was found to possess similar potency with the
quaternary epibatidium methiodide 26.

Table 4. Inhibition of [3H]Cytisine Binding at α4β2 Subtype nAChRs.

Compound

Ki ( nM )

(-)-epibatidine

0.079±0.016

(+)-epibatidine

0.14±0.02

(±)-epibatidine

0.16±0.03

(-)-cytisine

4.2±0.54

(-)-nicotine

8.0±4.5

(+)-nicotine

87±42

26

4.1±0.6

27

6.6±1.3

All values are the mean ±SEM of data from three experiments performed in triplicate
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Figure 3. Inhibition of [3H]Cytisine Binding at α4β2 Subtypes nAChRs
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Synthesis of endo-2-(Hydroxymethylpyridyl)-7-azabicyclo[2.2.1]heptane
Derivatives

Based on the high binding affinity and potent activity observed for the
3-pyridyl azetidine ester ABT-594 (13), the hybrid 7-azabicyclo[2.2.1]heptane
analogues were envisaged as potential nicotinic acetylcholine receptors ligands. The
synthesis of the hybrids 29a-c was envisaged to proceed via the important
intermediate developed from the total synthesis of epibatidine. The preparation of
endo alcohol 47 was achieved by the reduction of the corresponding ketone 38
(Scheme 10). The 7-azabicyclo[2.2.1]heptane-2-one 38 was synthesized as in the
previously described. Initially, reduction of the ketone 38 with DIBAl-H was
attempted. Though the yield of this reaction is 81%, a mixture of endo 47 and exo 48
isomers was obtained in a ratio of 47:48 / 7:3. Alternatively, when the bulkier
reducing reagent, lithium (tri-tert-butoxyallumino)hydride was applied, favorable
stereoselective results had been obtained. The first attempted reduction was performed
in diglyme only gave 39% yield. However, when the solvent was changed to THF, the
pure endo alcohol 47 was obtained stereoselectively ( >99%) in 78% yield.
Scheme 10
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Reagents
DIBAl-H, THF, -78oC, r. t., 10 h
LiAlH(tBuO)3 (0.5M in diglyme), 0oC, 2 h, r. t., 2 h
LiAlH(tBuO)3 (1M in THF), 0oC, 2 h, r. t., 2 h

47

48

Yield

70%

30%

81%

99%

trace

39%

99%

trace

78%

With pure endo alcohol (47) in hand, synthesis of the epibatidine pyridyl
ether series 29a-c proceeded. In a process as shown in Scheme 11, the endo alcohol
47 can be treated with the corresponding bromoalkylpyridine under Williamson ether

synthesis conditions. It seemed that this particular reaction was very sensitive to the
reaction conditions (temperature and time). After optimizing the reaction temperature
and time, it was found that 47 when treated with the bromomethylprydine 49a-c at
100oC for 15 h furnished the corresponding ester 50a-c in 66-83% yield. Table 5
summarized the optimized reaction conditions for synthesis of compound 49b. It was
found that when the reaction temperature is higher than 120oC, most of the
azabicyclic agent would be decomposed. The desired 2(-hydroxyalkylpyridyl)-7azabicyclo[2.2.1]heptane derivatives 29a-c were finally obtained by removal of the
Boc protectiving group with TFA (Scheme 11).
Table 5. Optimized Williamson Ether Synthesis Conditions

1
Temperature
80oC
Time
4h
Yield
------

2
100oC
4h
36%

3
100oC
15h
77%

4
120oC
15 h
50%

5
130oC
15 h
45%
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Scheme 11

Overall, a series of epibatidine pyridyl ethers have been successfully
synthesized. The binding affinity of these compound at nAChRs is currently under
investigation and will be reported elsewhere.
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Synthesis of exo-2-(Hydroxymethylpyridyl)-7-azabicyclo[2.2.1]heptane
Derivatives Efforts

A synthetic route to prepare exo-N-methyl-1-azabicylco-[2.2.1]heptane
51a-c was also investigated. As illustrated in Scheme 12, the acid chloride 53 was

prepared from the acid 52 using thionyl chloride in high yield. The reaction of acid
chloride 53 with sodium azide under phase transfer conditions afforded the acyl azide
54. The rearrangement of acyl azide 54 was done by letting it stand overnight in dry

dichloromethane over a drying agent. A slight excess of trifluoroacetic acid was then
added. This resulted the amide 55 in 65% overall yield.78
Scheme 12

Alkylation of 55 with methyl iodide and sodium hydride gave the N-methyl
derivative 56 in 78% yield, which was then transformed into the epoxides 57 (syn/anti
ratio ~ 1:3) with m-chloroperoxybenzoic acid in 81% yield. The mixture of epoxides
was then treated with potassium carbonate to remove the trifluoroacetyl protecting
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group in 75% yield to afford the syn-N-methylamino epoxide 58a as the sole product
(Scheme 13).79, 80 The yield of this step was improved from 65% to 75% by a rigorous
work-up of this reaction. Both dichloromethane and ether were used to extract the
product as it was found that if just ether was used as described in the literature,
product was still found in the water layer as seen by T.L.C. It is noteworthy that a
single diastereoisomer 58a was obtained from the hydrolysis reaction of 57.
Alternatively, if the mixture of epoxides 57 was treated with methanolic potassium
hydroxide, a mixture of syn and anti epoxides 58a : 58b (3:1) was obtained.38 In a
similar manner as described above, dichloromethane and ether were both used for
extraction to improve the yield from 70% to 91%.
Scheme 13

The mixture of epoxides 58a and 58b was heated at 160°C in
N-methylpyrrolidone (NMP)/potassium carbonate for 72 h and then allowed to cool to
room temperature over 12 h. After work-up, a mixture was expected to be obtained

45

corresponding to the ring closure of exo-isomer 59 and endo-isomer 60 (Scheme
14).80
Scheme 14

The best yield of this step was only 12%. However, it was determined that the
exo-isomer 59 was formed by intramolecular cyclization reaction if the pure epoxide
57 was cyclized, the yield was increased to 55% this way.

Some difficulties were encountered with the attempted Williamson ether
synthesis of the exo-N-methyl alcohol 59 and the corresponding bromalkylpyridine.
The first attempted ether synthesis of exo-N-methyl alcohol 59 was performed with
the same ether synthesis condition of endo-N-Boc alcohol 47 using NaH in DMF.
A very complex mixture resulted as determined by TLC. Alternatively, a weaker base
KOH was attempted exploiting the formation of the ether in DMSO. Unfortunately,
none of the desired ethers were obtained. Competing N-alkylation gave a complex
mixture of intractable materials. The third attempt of a Williamson ether synthesis was
performed with stronger base n-BuLi in THF at room temperature only gave starting
material. However, the decomposition of azabicyclic ring was observed when the
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temperature was increased to 60oC. The lack of reactivity of exo-N-methyl alcohol
was surprising. Though the N-methyl group has been identified as a good protecting
group for amines, there is a fine line between the stability and the decomposition of
the azabicyclic ring in basic environment.
Scheme 15

Two alternative routes can be attempted. The first is the conversion of the
N-methyl group to a N-carbonyl group. This will reduce the nucleophilicity of the
nitrogen atom and prevent quaternization (Scheme 16). The second route started from
endo-N-Boc alcohol 47. Treatment of 47 under Mitsunobu reaction condition should
then afford the compound 63 (Scheme 16). Although these two methods were
exploited, the yields were relatively low with the tiny scale after separation and
purification. Further attempts will be reinvestigated at a later date.
Scheme 16
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Synthesis Acetylcholine Analogues

Acetylcholine is a flexible molecule with many possible conformations. The
topography of the ion-channel of the acetylcholine receptor is not fully known.
Likewise, the binding conformation of acetylcholine is unknown. By constructing
several rigid conformations of acetylcholine and its derivatives, a better understanding
of its spatial geometry within the receptor, and ultimately the three-dimensional
receptor structure can be achieved.
With the important intermediate azabicyclic alcohol 59 in hand, the syntheses
of the rigid acetylcholine analogues were also carried out (Scheme 17). The exo
alcohol 59 was treated with freshly distilled acetic anhydride ( Ac2O) in the presence
of dry pyridine at room temperature. High yield was achieved if the chromatography
solvent system contained NH4OH in order to neutralize the acidic sites of the silica
gel. The exo-2-acetoxy-7-methyl-7-azabicyclo[2.2.1]heptane 64 was converted into
the oxalic acid salts as white solid for biological testing. The quaternary
exo-2-acetoxy-7-methyl-7-azabicyclo[2.2.1]heptane methiodide 65 was synthesized
by treating the starting material 64 with methyl iodide ( CH3I) in refluxing THF. Upon
completion of the methylation, the solvent was removed and the resultant yellow solid
was washed with ether to afford the quaternary salt 65 in high yield. The purity of the
resulting salt 65 was suitable for biological testing. The biological activity of 64-65 is
currently under investigation and will be reported elsewhere in due course.
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Scheme 17
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CONCLUSION
Three novel series of epibatidine analogues have been prepared and
evaluated as potential nAChR ligands. Among them, the novel quaternary
epibatidinium salt 26 and bis-epibatidine derivative 27 exhibited significantly high
binding affinity at nAChRs relative to nicotine and cytisine. It is apparent from this
study that a new class of bis-epibatidine derivatives would act as a potential potent
nAChR ligand. In addition, a series of pyridyl ether epibatidine analogues have been
identified

and

three

endo-2-(hydroxymethylpyridyl)-7-azabicyclo[2.2.1]heptane

compounds have been successfully synthesized. The structure-activity relationship
studies of these analogues should offer some interesting insights into the elucidation
of the neuronal nAChR pharmacophore and will be useful in the further studies aimed
a development of selective nAChR therapeutic agent. Moreover, two more new rigid
2-acetoxy-7-azabicyclo[2.21]heptane derivatives have been prepared. These studies
will certainly provide additional information with regard to the structure-activity
relationships and pharmacology of the nAChR ligand epibatidine. Overall, these
studies may lead to the development of new pharmacological strategies and
therapeutic agents for nAChR research.
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EXPERIMENTALS

General Information

z All chemicals were purchased from Aldrich Chemical Co., Milwaukee, WI, unless

otherwise noted. Ethyl alcohol, absolute-200 proof, was purchased from AAPER
Alcohol and Chemical Co., Shelbyville, KY.

Bakerdry® THF, Bakerdry®

dichloromethane, Bakerdry® acetonitrile and Bakerdry® mechanol purchased from
Mallinkrodt Baker Inc., Philisburg, NJ, and stored under argon. Benzene, hexane
and toluene were dried by distillation over sodium pieces using benzophenone as
the indicator and stored under nitrogen. Anhydrous DMF was purchased in a
sure-seal bottle from Aldrich Chemical Co. Acetic acid (100 mL) was dried by
simple distillation from acetic anhydride (1 mL).

z Chromatography was accomplished on silica gel ( Silica Gel 60, 200-400 mesh,

Natland International Corp, Morrisvile, NC). Petroleum ether refers to pentanes
with a boiling point range of 30-60 °C.

z NMR spectra were recorded on Varian-Gemini 400MHz and Varian Gemini 300

MHz multiprobe spectrometers as indicated. Both 1H NMR spectra and 13C NMR
spectra were recorder for the freebase unless otherwise indicated. Chemical shifts
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are reported as δvalues from Deuterated chloroform (CDCl3) or as noted,
tetramethylsilane (TMS) (Cambridge isotope Laboratories) were employed as the
internal standards.

z Elemental analyses were determined by Atlantic Microlabs Inc., Norcross, GA for

the corresponding oxalate salts and hydrochloride salts.

z Reported melting points were recorded on a Hoover Mel-Temp apparatus and are

uncorrected.

General Procedure for the Preparation of Hydrochloride Salts.

The freebase

compound (50 mg) was dissolved in THF (1-2 mL). This solution was added to a
cooled solution of saturated hydrogen chloride in ether. The hydrogen chloride salt
precipitated instantaneously with the mixing of the two solutions. The precipitate was
immediately collected by vacuum filtration to prevent decomposition of acid sensitive
compounds. The salt was washed with anhydrous ether three times. Some analytical
samples contained minute amounts of water despite drying (48 h under vacuum).

Methyl Propiolate (31): To a solution of propiolic acid (25 g, 0.36 mol) in dry

methanol ( 200 mL) was added via syringe freshly distilled boron trifluoride etherate
( 93 mL, 0.76 mol). The solution was refluxed for 1.5 h and further stirred at room
temperature for 4 h. Water ( 200 mL) was added, the mixture was extracted with
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dichloromethane ( 100 mL). The organic layer was removed, and the aqueous portion
was extracted with 3 × 100 mL of dichloromethane. The combined organic layers
were washed sequentially with 200 mL of water and 100 mL of brine. The organic
solution was dried over sodium sulfate. The solvent was removed under reduced
pressure and the residue was distilled in vacuo to give pure 31 (19 g, 60% ). bp
42-44°C/ 30 mmHg; 1H NMR ( 400 MHz, CDCl3) δ3.78 ( 3H, s), 2.90 (1 H, s).

Methyl 3-bromopropiolate (32): To a magnetically stirred solution of compound 31

( 10 g, 0.12 mol) in freshly distilled acetone ( 350 mL) at room temperature, silver
nitrate ( 2 g, 12 mol) was added, followed by N-bromosuccinimide ( 24 g, 0.14 mol)
all at once. Stirring was continued for 3 h while the homogeneous solution turned
cloudy and then a grayish precipitate developed. Careful removal of acetone by rotary
evaporation under water pump pressure at room temperature gave a yellow oil. The
residue distilled by vacuum bulb-to-bulb distillation to afford a yellow solid ( 14 g,
74%) 1H NMR (400 MHz, CDCl3/TMS) δ3.73 ( 3 H, s).

N- (tert-Butoxycarbonyl)-pyrrole (34): To a stirred solution of pyrrole ( 7 mL, 0.1

mol) in dry CH3CN ( 100 mL) was added DMAP ( 1.2 g , 0.01 mol) and Boc2O ( 26 g,
0.12 mol) at room temperature. Evolution of gas commenced, and after 0.5 h a clear
solution was obtained. The whole reaction mixture was stirred at room temperature
for 48 h to ensure complete reaction. The solvent was carefully removed under
reduced pressure to give the product 34 as yellow oil (16 g, 99% ) 1H NMR ( 400
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MHz, CDCl3/TMS) δ7.24 ( 2 H, d, J = 2.1Hz ), 6.21 ( 2 H, d, J = 2.1Hz ), 1.59 ( 9 H,
s).

Methyl 2-bromo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hepta-2,5-diene-2carboxylate (35): A mixture of methyl 3-bromopropiolate (32) ( 8.2 g, 0.05 mol) and

N-Boc-pyrrole ( 42 g, 0.25 mol) was stirred at 85-90oC under nitrogen for 30 h. The
resulting mixture was cooled to room temperature and subjected to column
chromatography (EtOAc : Hexane, 1 : 15 ) to give the desired product 35 as a slightly
yellow oil ( 22 g, 67% ). 1H NMR (400 MHz, CDCl3/TMS) δ7.12 (2 H, br s), 5.47
( 1 H, s), 5.12 ( 1 H, s), 3.79 ( 3 H, s), 1.41 ( 9 H, s).

7-(tert-Butoxycarbonyl)-3-(methoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2-one
(36): To a solution of 35 ( 10 g, 30 mmol) and triethylamine (20 mL, 150 mmol) in

dry acetonitrile ( 60 mL) was added dropwise a solution of diethylamine ( 3.5 mL, 33
mmol) in dry acetonitrile ( 40 mL) under a nitrogen atmosphere. The mixture was
stirred at room temperature for 2 h. A 10% HCl (100 mL) solution was then added
slowly. The reaction mixture was stirred for another 3.5 h. Water (100 mL) was added,
and the mixture was extracted with dichloromethane (3 × 60 mL). The
dichloromethane was dried with sodium sulfate and concentrated under reduced
pressure. The residue was chromatographed ( silica gel, EtOAc : Hexane, 1: 6 ) to
afford the β-keto ester 36 ( 6.9 g, 86% ) as an yellow oil ( endo : exo, 7 : 1). 1H NMR
( 400 MHz, CDCl3 ) δ6.95 ( 0.88 H, dd, J = 3.6 Hz ), 6.77 ( 0.12 H, s), 6.36 ( 0.12H,
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s), 6.35 ( 0.88H, d, J = 2.8 Hz ), 5.42 ( 0.12 H, s), 5.09 ( 0.88 H, s), 4.69 ( 1 H, s), 3.75
( 2.64 H, s ), 3.73 ( 0.36 H, s ), 3.40 ( 0.88 H, d, J = 3.2 Hz ), 2.93 ( 0.12 H, s ), 1.44
( 9 H, s).

7-(tert-Butoxycarbonyl)-3-(methoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one
(37): A suspension of 36 ( 4.0 g, 15 mmol) and 10% Pd / C ( 500 mg) in dry methanol

( 45 mL ) was vigorously stirred under a hydrogen atmosphere (1 atm ) at room
temperature overnight. The catalyst was removed by filtration through a pad of celite
and the filtrate was concentrated under reduced pressure. Flash chromatograph on
silica gel (EtOAc : Hexane, 1: 6 ) afforded 37 ( 3.9 g, 97 % ) as colorless oil ( endo :
exo, 3 : 2). 1H NMR ( 400 MHz, CDCl3 ) δ4.84 ( 0.6 H, d, J = 3.6 Hz ), 4.73 ( 0.4 H,
t, J = 4.4 Hz), 4.36 ( 0.6 H, d, J = 4.5 Hz ), 4.32 ( 0.4 H, d, J = 6.0 Hz ), 3.76( 1.2 H,
s ), 3.73 ( 1.8 H, s ), 3.45( 0.4 H, d, J = 4.2 Hz ), 2.99 ( 0.6 H, s ), 2.00-2.07 ( 2 H, m),
1.60-1.73 ( 2 H, m ), 1.45( 9 H, s).

7-(tert-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one (38): A solution of the

β-keto ester 37 ( 1.4 g, 5 mmol) in 10% HCl ( 110 mL) was heated at 100-110 oC for 3
h under nitrogen atmosphere. The solution was allowed to cool to room temperature
and evaporated under reduced pressure. The trace of remaining water was removed by
azeotropic distillation with EtOH and then dried thoroughly under vacuum. The gray
residue was dissolved in dichloromethane (60 mL) and Et3N (2.8 mL, 20 mmol ) and
Boc2O (2.2 g, 10 mmol) were added. The solution was stirred for 24 h at room
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temperature and then washed with saturated Na2CO3 solution. The organic layer was
dried (Na2SO4), filtered, and concentrated to provided a yellow oily residue which
was chromatographed (SiO2, EtOAc : Hexane, 1 : 5 ) to afford the ketone 38 ( 0.88g,
84% ) as a white solid. mp 60-62oC. 1H NMR ( 400 MHz, CDCl3 ) δ 4.56 ( 1 H, t, J =
4.4 Hz ), 4.25 ( 1 H, d, J = 5.2 Hz ), 2.46 ( 1 H, dd, J = 5.2 Hz ), 1.99-2.04 ( 3 H, m ),
1.59-1.68 (2 H, m ), 1.46 ( 9 H, s).

2-Amino-5-iodopyridine (40): A mixture of 2-aminopyridine 39 ( 9.4 g, 0.1 mol),

periodic acid dehydrate ( 4.5 g, 0.02 mol) and iodine ( 10 g, 0.04 mol ) was heated in
a mixed solution of acetic acid ( 60 mL), water ( 12 mL) and H2SO4 ( 1.8 mL) at 80oC
for 4 h. The mixture was then poured into aqueous Na2S2O3 to remove unreacted
iodine and extracted with ether. The extract was washed with aqueous diluted NaOH,
dried (Na2SO4), and concentrated in vacuo. The residue was purified by column
chromatography on silica gel with ethyl acetate as eluent and then recrystallized from
ethanol to afford the colorless prisms of 40 ( 13 g, 60% ): 1H NMR (400 MHz, CDCl3 )
δ 8.21 ( 1 H, d, J = 1.5 Hz ), 7.64 ( 1 H, dd, J = 2.1, 1.8 Hz ), 6.38 ( 1 H, d, J = 3.6
Hz ), 4.24 ( 2 H, br s).

2-Chlolo-5-iodopyridine (41): To a stirred solution of 2-amino-5-iodopyridine 40 (11

g, 0.05 mol) in 37% concentrated HCl ( 100 mL) were added sodium nitrite (17 g,
0.25 mol) at ice bath, the temperature being kept around 0oC during the addition. The
reaction was then continued for 1 h at room temperature and then quenched by
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addition of aqueous solution of NaOH (20 mL ). The mixture was extracted with
ether and the extract was washed with water, dried and concentrated. The residue
was purified by column chromatography on silica gel and then recrystallized from
ethanol to give pale yellow plates of 41 ( 7.5 g, 63% ). 1H NMR ( 300 MHz, CDCl3 )
δ8.60 ( 1 H, d, J = 2.1 Hz ), 7.94 ( 1 H, d, J = 11.1 Hz ), 7.14 (1H, d, J = 8.1 Hz ). 13C
NMR (CDCl3 ) δ151.1, 146.4, 142.2, 121.6, 86.2.

exo-2-(2-Chloro-5-pyridinyl)-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2
-ol (42): A solution of 2-chloro-5-iodopyridine 41 ( 260 mg, 1.1 mmol) in dry ether (5

mL) and dry THF (2.5 mL) at -78 oC was added n-BuLi (0.80 mL, 1.4 M solution in
hextane, 1.2 mmol) dropwise. The mixture was stirred at -78oC for 45 min before a
solution of ketone 38 (210 mg, 1.0 mmol) in ether (3 mL) was added dropwise. The
mixture was stirred at -78oC for 3 h and then warmed to -50oC and stirred for another
30 min. Saturated aqueous NH4Cl (2 mL) was added, and the mixture was allowed to
warm to room temperature. Water (5 mL) was added, and the organic layer was
separated. The aqueous phase was extracted with EtOAc (10 mL), and the combined
organic layers were dried (Na2SO4) and concentrated. The residue was
chromatographed on silica gel ( EtOAc : Hexane, 1 : 3) to give the tertiary alcohol 42
( 0.3g, 92%) as a white solid. mp 147-149oC. 1H NMR ( 400 MHz, CDCl3 ) δ8.59 ( 1
H, d, J = 2.4 Hz ), 7.85 ( 1 H, dd, J = 2.4, 6.0 Hz ), 7.26 ( 1 H, d, J = 6.0 Hz ), 4.28 ( 1
H, s), 4.20 ( 1 H, s), 2.71 ( 1 H, br s), 2.36 ( 2 H, m), 1.64-1.9 (4 H, m ), 1.44 ( 9 H, s).

57

endo-(2-Chloro-5-pyridinyl)-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane
(43): To a solution of the tertiary alcohol 42 ( 130 mg, 0.4 mmol) and

4-(dimethylamino)pyridine (DMAP, 73 mg, 0.6 mmol) in dry CH3CN ( 5 mL) was
added methyl oxalyl chloride ( 0.055 mL, 0.6 mL). The mixture was stirred for 10
min at room temperature under nitrogen and then diluted with EtOAc (20 mL). The
mixture was then washed successively with saturated aqueous NaHCO3 (10 mL) and
H2O (10 mL). The organic portion was dried (Na2SO4), and the solvent was removed
under reduced pressure. The residue was evaporated twice with toluene to afford the
methyl oxalyl ester. Without further purification, the crude ester was added to a
mixture of Bu3SnH (0.18 mL, 0.63 mmol) and freshly recrystalized 2,
2’-azobis(isobutyronitrile) (AIBN, 10 mg) in dry toluene ( 5 mL) under nitrogen. The
mixture was heated at 100oC for 1 h. The solvent was removed under reduced
pressure and the residue was purified by chromatography ( EtOAc : Hexane, 1 : 9) to
afford the endo-isomer (116 mg, 94%) as a white solid. mp 80-82oC. 1H NMR ( 400
MHz, CDCl3 ) δ 8.23 ( 1 H, d, J = 2.4 Hz ), 7.46 ( 1 H, dd, J = 3.2, 8.4 Hz ), 7.27 ( 1 H,
d, J = 2.4 Hz ), 4.3 ( 2 H, m), 3.44 ( 1H, m), 2.28 ( 1 H, m), 1.83 ( 1 H, m), 1.49-1.85
(2 H, m), 1.46 ( 9 H, s), 0.94-1.43 ( 2 H, m).

exo-2-(2-Chloro-5-pyridinyl)-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane
(44): Epimerization of 43. A mixture of 37 ( 100 mg, 0.33 mmol) and t-BuOK ( 190

mg, 1.7 mmol) in t-butyl alcohol ( 5 mL) was heated to reflux for 45 h under nitrogen.
The solvent was evaporated, and the residue was chromatographed ( EtOAc : Hexane,
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1 : 9) to afford the endo-isomer 43 and the exo-isomer 44 (33 mg, 50% based on
recovered 43) as a white solid. mp 67-69oC. 1H NMR ( 400 MHz, CDCl3 ) δ 8.23 ( 1
H, d, J = 1.2 Hz ), 7.62 ( 1 H, d, J = 7.6 Hz ), 7.22 ( 1 H, d, J = 1.2 Hz ), 4.35 ( 1 H, br
s), 4.13 ( 1 H, br s), 2.84 (1 H, dd, J = 4.8, 4.0 Hz ), 1.97 ( 1 H, d, J = 8.8 Hz ), 1.80
( 3 H, m), 1.55 ( 2 H, m), 1.45( 9 H, s).

exo-2-(2-Chloro-5-pyridinyl)-7-azabicyclo[2.2.1]heptane (4): To a solution of 44

( 156 mg, 0.5 mmol) in dichloromethane ( 5.0 mL), trifluoroacetic acid ( 0.5 mL, 6.5
mmol) was added dropwise with stirring under nitrogen. The mixture was stirred for 3
h at room temperature and rendered basic with saturated Na2CO3 ( 10 mL). The
organic layer was separated, and the water phase was extracted with dichloromethane.
The organic layers were combined, dried and concentrated under reduced pressure.
The residue was purified by chromatography (SiO2, CH2Cl2 : MeOH : Et3N, 90 : 10 :
1) to give 2 ( 133 mg, 98% ) as a white solid. mp 50-51oC. 1H NMR ( 400 MHz,
CDCl3 ) δ 8.26 ( 1 H, d, J = 3.6 Hz ), 7.76 ( 1 H, dd, J = 3.6, 8.0 Hz ), 7.22 ( 1 H, d, J
= 3.6 Hz ), 3.79 ( 1 H, br s), 3.56 ( 1 H, br s ), 2.77 ( 1 H, dd, J = 6.4 Hz ), 1.91 ( 1 H,
m ), 1.50-1.63 (5 H, m )

exo-2-(2-Chloro-5-pyridinyl)-7-methyl-7-azabicyclo[2.2.1]heptane

(45):

To

a

stirred solution of 4 (42 mg, 0.2 mmol) and 37% aqueous formaldehyde (0.16 mL, 2
mmol) in 1.5 mL of acetonitrile under an atmosphere of nitrogen was added sodium
cyanoborohydride ( 38 mg, 0.6 mmol). An exothermic reaction ensued and the white
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gray solid precipitated. The reaction mixture was stirred for 10 minutes, and then
glacial acetic acid was added dropwise until the solution tested neutral on pH paper.
Stirring was then continued for an additional 30 minutes. The whole solution was
evaporated under reduced pressure, and 1 mL of 10% NaOH solution was added to
the residue. The resulting mixture was extracted with ether ( 3 × 2 mL ). The
combined ether extracts were washed with 5% NaOH solution ( 2 mL ), and then with
10% HCl ( 3 × 1 mL ). The acid extracts were combined and neutralized with solid
NaOH and then extracted with ether ( 3 × 2 mL ). The combined ether extracts were
dried with sodium sulfate. After filtering, the solvent was removed under reduced
pressure. Purification of the residue was achieved by flash chromatography (SiO2,
CH2Cl2: MeOH: Et3N, 180:20:1) to yield 45 as white solid (40 mg, 94% yield). 1H
NMR (300 MHz, CDCl3) δ 8.28 ( 1 H, d, J = 2.7 Hz ), 7.88 ( 1 H, dd, J = 2.7 Hz ),
7.21 ( 1 H, d, J = 6.4 Hz ), 3.33 ( 1 H, t, J = 4.5 Hz ), 3.13 ( 1 H, d, J = 3.9 Hz ), 2.65
( 1 H, dd, J = 4.5 Hz ), 2.25 ( 3 H, s), 1.82-1.95 ( 3 H, m), 1.68 ( 1 H, m), 1.42 ( 2 H,
m). 13C NMR (CDCl3) δ 148.9, 148.8, 141.7, 138.1, 123.8, 67.6, 61.3, 45.4, 41.5, 34.7,
26.5, 25.5.

exo-2-(2-Chloro-5-pyridinyl)-7-methyl-7-azabicyclo[2.2.1]heptane

methiodide

(26): To a stirred solution of 45 (34 mg, 0.15 mmol) in freshly distilled THF (3 mL)

under an atmosphere of nitrogen was added CH3I (0.3 mL, 4.8 mmol) dropwise. The
solution was heated to reflux for 3 h. The solution was removed under reduced
pressure and the resulting fine powder was triturated with warm ether to yield 39 as a
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yellow powder (42 mg, 83% yield). 1H NMR (400 MHz, CD3OD) δ 8.45 ( 1 H, d),
7.88 ( 1 H, dd), 7.51 ( 1 H, d), 4.83 ( 1 H, d), 4.22 ( 1 H, t), 3.80 ( 1 H, t), 3.21 ( 3 H,
s), 2.87 ( 3H, s), 2.70 ( 2 H, m), 2.548( 2 H, m), 2.14 (2 H. m). 13C NMR (CD3OD) δ
149.5, 147.2, 137.4, 136.3, 124.3, 73.7, 72.5, 45.6, 44.9, 42.9, 34.7, 27.9, 26.1 .
Anal. Calc. for C13H18N2ClI•0.5 H2O: C, 41.79%; H, 5.12%; N, 7.50%. Found: C
42.05%, H, 4.95%, N, 7.36%

N, N’-Decamethylene bis-exo-2-(2-chloro-5-pyridinyl)-7azabicyclo[2.2.1]heptane
(46): A mixture of epibatidine 4 ( 52 mg, 0.25 mmol) and 1, 10-diiododecane ( 50 mg,

0.125 mmol) in 5 mL of freshly distilled toluene in the presence of N,
N’-diisopropylethylamine ( 0.11 mL, 0.75 mmol) was heated with stirring at 110oC
under nitrogen for 10 days. The solvent was removed under reduced pressure and
water ( 5 mL ) was added to the residue. The aqueous layer was then extracted with
dichloromethane. The extract was dried with sodium sulfate and concentrated under
reduced pressure. The residue was purified by flash chromatography (SiO2, CH2Cl2 :
MeOH, 30:1) to yield 46 as thick, brown oil ( 49 mg, 71% yield). 1H NMR (400 MHz,
CDCl3) δ 8.32 ( 2 H, d, J = 2.4 Hz ), 7.90( 2 H, dd, J = 2.4, 6.4 Hz ), 7.19 ( 2 H, d, J =
8.0 Hz ), 3.45 ( 2 H, s ), 3.20 ( 2 H, s), 2,63 ( 2 H, t, J = 4.4 Hz ), 2.41 ( 2 H, m), 2.32
( 2 H, m), 1.82-1.89 ( 6 H, m), 1.70 ( 2 H, m), 1.40-1.48 ( 8 H, m), 1.27 ( 12 H, m).
13

C NMR (CDCl3) δ 149.0 (2), 148.8 (2), 142.1 (2), 138.3 (2), 123.7 (2), 65.5 (2),

59.4 (2), 47.3 (2), 45.2 (2), 41.5 (2), 29.6 (6), 27.7 (2), 26.8 (2), 26.1 (2) .
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The free base ( 46 ) was converted into the HCl salt.
N, N’-Decamethylene bis-exo-2-(2-chloro-5-pyridinyl)-7-azabicyclo[2.2.1]heptane
hydrochloride (27): Anal. Calc. for C32H44N4Cl2•2HCl•3H2O: C, 56.31%; H, 7.68%;

N, 8.21%. Found: C, 56.54%, H, 7.47%, N, 7.89%.

N, N’-Decamethylene bis-exo-2-(2-chloro-5-pyridinyl)-7-azabicyclo[2.2.1]heptane
methiodide (28): Compound 46 (30 mg, 0.054 mmol) was dissolved in 3.0 mL of

absolute ethanol. Under an atmosphere of nitrogen, iodomethane ( 3.0 mL, 48 mmol,
passed through a small column of anhydrous potassium carbonate) was added, and the
reaction mixture was allowed to stir and reflux for 3 days. The solvent was removed
under reduced pressure and the residue was washed with ethyl ether to give 28 as
crude brown solid (45 mg, 73% yield).

endo-7-[(1,1-Dimethylethoxy)carbonyl]-7-azabicyclo[2.2.1]heptan-2-ol (47): To a

stirred solution of ketone 38 ( 211 mg, 1 mmol) in freshly stilled THF ( 2 mL) was
added dropwise lithium(tri-tert-butoxyalumino)hydride (1.0 M in THF) ( 3 mL, 3
mmol). The solution was stirred for 2 h at 0oC and then for another 2 h at room
temperature. The reaction was quenched by addition of water ( 5 mL ). The mixture
was filtered through a pad of silica gel (3 cm), which was then washed with ethyl
ether. After evaporation of the solvent from the filtrate, the residue was subsequently
chromatographed over silica gel ( ethyl acetate : hexane = 1 : 5 ) to furnish 47 as a
white solid ( 166 mg, 78% yield). mp 44-45.5oC. 1H NMR ( 400 MHz, CDCl3 ) δ 4.35
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( 1 H, t, J = 4.8 Hz ), 4.13 ( 2 H, dd, J = 7.2 Hz ), 2.15-2.22 ( 2 H, m), 1.75-1.80 ( 1 H,
m), 1.60-1.66 ( 2 H, m), 1,45 ( 9 H, s)，1.27 ( 1 H, d, J = 2.8 Hz ). 13C NMR ( CDCl3 )
δ 155.7, 79.8, 70.5, 59.9, 57.3, 38.9, 29.8, 28.2 ( 3 ), 20.7.

endo-2-[Hydroxymethyl-(2-pyridinyl)]-7-[(1,1-dimethylethoxy)carbonyl]-7-azabi
cyclo[2.2.1]heptane (50a): To a stirred solution of endo-alcohol 47 ( 85 mg, 0.4

mmol) in anhydrous DMF ( 1 mL) at ice bath was added NaH ( 60% in oil, 40 mg, 1
mmol) slowly. The whole mixture was stirred at room temperature for 1 h.
Subsequently, a solution of 2-(bromomethyl)pyridine hydrobromide ( 202 mg, 0.8
mmol) in anhydrous DMF ( 3 mL) was added slowly. The reaction mixture was then
stirred at 90oC-100oC for 15 h. After the mixture was cooled, the solvent was removed
under reduced pressure. The residue was partitioned between ether and water. The
organic layer was then washed with saturated Na2CO3 solution and water, dried
( Na2SO4) and evaporated. The crude product was purified by silica gel column
chromatography ( ethyl acetate : hexane = 1 : 1 ) to give the desired product 50a ( 94
mg, 83% yield) as white solid. mp. 65-68oC. 1H NMR ( 400 MHz, CDCl3 ) δ 8.53 ( 1
H, d, J = 0.8 Hz ), 7.68 ( 1 H, t, J = 2.0 Hz ), 7.42 ( 1 H, d, J = 8.0 Hz ), 7.18 ( 1 H, t, J
= 4.8, 2.0 Hz ), 4.56 ( 2 H, s ), 4.32 ( 1 H, s), 4.16 ( 1 H, s ), 4.09 (1 H, t, J = 4.8 Hz ),
2.15 ( 2 H, m), 1.78 ( 1 H, m), 1.64 ( 1 H, m), 1.45 ( 9 H, s), 1.26 ( 2 H, m). 13C NMR
(CDCl3 ) δ 158.2, 155.6, 149.1, 136.6, 122.4, 121.4, 79.7, 78.4, 72.6, 58.2, 56.8, 37.0.
29.7, 28.2 ( 3 ), 21. 2.
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endo-2-[Hydroxymethyl-(3-pyridinyl)]-7-[(1,1-dimethylethoxy)carbonyl]-7-azabi
cyclo[2.2.1]heptane (50b): To a stirred solution of endo-alcohol 47 ( 85 mg, 0.4

mmol) in anhydrous DMF ( 1 mL) at ice bath was slowly added NaH ( 60% in oil, 40
mg, 1 mmol). The mixture was stirred at room temperature for 1 h. Subsequently, a
solution of 3-(bromomethyl)pyridine hydrobromide ( 200 mg, 0.8 mmol) in
anhydrous DMF ( 3 mL) was added slowly. The reaction mixture was then stirred at
90oC-100oC for 15 h. After the mixture was cooled, the solvent was removed under
reduced pressure. The residue was partitioned between ether and water. The organic
layer was washed with saturated Na2CO3 solution and water, dried ( Na2SO4) and
evaporated. The crude product was purified by silica gel column chromatography
( ethyl acetate : hexane = 1 : 1 ) to give the desired product 50b ( 83 mg, 73% yield)
as white solid. mp 73-74oC

1

H NMR ( 400 MHz, CDCl3 ) δ 8.58 ( 1 H, s ), 8.55 ( 1

H, d, J = 3.6 Hz ), 7.65 ( 1 H, d, J = 2.0 Hz ), 7.27 ( 1 H, dd, J = 4.8, 2.4 Hz ), 4.45 ( 2
H, s), 4.29 ( 1 H, s) , 4.13 ( 1 H, s), 4.03 ( 1 H, t ), 2.16 ( 1 H, m ), 2.06 ( 1 H, m), 1.76
( 1 H, m ), 1.61 ( 1 H, m ), 1.43 ( 9 H, s ), 1.24 ( 1 H, m). 13C NMR ( CDCl3 ) δ 155.6,
149.2, 149.1, 135.3, 133.5, 123.4, 79.8, 78.3, 69.3, 58.2, 56.9, 37.1, 29.7, 28.3 ( 3 ),
21.2.

endo-2-[Hydroxymethyl-(4-pyridinyl)]-7-[(1,1-dimethylethoxy)carbonyl]-7-azabi
cyclo[2.2.1]heptane (50c): To a stirred solution of endo-alcohol 47 ( 85 mg, 0.4

mmol) in anhydrous DMF ( 1 mL) at ice bath was added NaH ( 60% in oil, 40 mg, 1
mmol) slowly. The whole mixture was stirred at room temperature for 1 h.
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Subsequently, a solution of 4-(bromomethyl)pyridine hydrobromide ( 202 mg, 0.8
mmol) in anhydrous DMF ( 3 mL) was added slowly. The reaction mixture was then
stirred at 90oC-100oC for 15 h. After the mixture was cooled, the solvent was removed
under reduced pressure. The residue was partitioned between ether and water. The
organic layer was washed with saturated Na2CO3 solution and water, dried ( Na2SO4)
and evaporated. The crude product was purified by silica gel column chromatography
( ethyl acetate : hexane = 1 : 1 ) to give the desired product 50c ( 75 mg, 66% yield)
as white solid. mp. 78-80oC. 1H NMR ( 400 MHz, CDCl3 ) δ 8.52 ( 2 H, d, J = 4.4
Hz ), 7.17 ( 2 H, d, J = 4.8 Hz ), 4.41 ( 2 H, s), 4.26 ( 1 H, s ), 4.11 ( 1 H, s ), 4.00 ( 1
H, t, J = 4.8 Hz ), 2.14 ( 1 H, t, J = 2.8 Hz ), 2.02 ( 1 H, t, J = 4.4 Hz ), 1.75 ( 1 H, s ),
1.58 ( 1 H, m ), 1.50 ( 1 H, m), 1.42 ( 9 H, s ), 1.18 ( 1 H, m).

endo-2-[Hydroxymethyl-(2-pyridinyl)]-7-azabicyclo[2.2.1]heptane (29a): To a

solution of ester 50a ( 60 mg, 0.2 mmol) in dry CH2Cl2 ( 2 mL) was added
trifluoroacetic acid ( 0.2 mL, 2.6 mmol) dropwise with stirring under nitrogen. The
mixture was stirred for 3 h at room temperature and rendered basic with saturated
Na2CO3 ( 3 mL). The organic layer was separated, dried ( Na2SO4), and concentrated
under reduced pressure. The residue was purified by chromatography ( CH2Cl2 :
MeOH : NH4OH, 100 : 10 : 1 ) to give 29a as colorless solid ( 37 mg, 93% yield). mp
132-134oC.

1

H NMR ( 400 MHz, CDCl3 ) δ 8.54 ( 1 H, d, J = 4.4 Hz ), 7.70 ( 1 H, t,

J = 7.6 Hz ), 7.45 ( 1 H, d, J = 7.6 Hz ), 7.18 ( 1 H, t, J = 6.0 Hz ), 4.58 ( 2 H, s), 4.03
( 1 H, t , J = 5.2 Hz ), 3. 74 ( 1 H, t, J = 4.4 Hz ), 3.60 ( 1 H, t, J = 4.4 Hz ), 2.12 ( 1 H,
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m), 2.01 ( 1 H, m), 1.78 ( 1 H, s), 1.58 ( 1 H, m), 1.44 ( 1 H, m), 1.25 ( 1 H, s ). 13C
NMR (CDCl3 ) δ 158.8, 149.1, 136.6, 122.3, 121.4, 80.1, 72.7, 58.5, 57.1, 37.1, 30.9,
22.3.

endo-2-[Hydroxymethyl-(3-pyridinyl)]-7-azabicyclo[2.2.1]heptane (29b): To a

solution of ester 50b ( 72 mg, 0.24 mmol) in dry CH2Cl2 ( 2 mL) was added
trifluoroacetic acid ( 0.2 mL, 2.6 mmol) dropwise with stirring under nitrogen. The
mixture was stirred for 3 h at room temperature and rendered basic with saturated
Na2CO3 ( 3 mL). The organic layer was separated, dried ( Na2SO4), and concentrated
under reduced pressure. The residue was purified by chromatography ( CH2Cl2 :
MeOH : NH4OH, 100 : 10 : 1 ) to give 29b as yellow solid ( 43 mg, 90% yield). mp.
136-138oC 1H NMR ( 400 MHz, CDCl3 ) δ 8.57 ( 1 H, s ), 8.53 ( 1 H, d, J = 4.4 Hz ),
7.69 ( 1 H, d, J = 7.6 Hz ), 7.30 ( 1 H, dd, J = 4.4, 2.4 Hz ), 4.47 ( 2 H, s), 4.03 (1 H,
m, ), 3.77 ( 1 H, t, J = 4.8 Hz ), 3.65 ( 1 H, t, J = 4.8 Hz ), 3.02 ( N-H, s), 2.11 ( 1 H,
m), 2.05 ( 1 H, m), 1.65 ( 1 H, m), 1.57 ( 1 H, m ), 1. 51 ( 1 H, m), 1.16 ( 1 H, dd, J =
3.6 Hz ).

13

C NMR (CDCl3 ) 149.03, 149.00, 135.4, 133.7, 123.4, 79.4, 69.3, 58.5,

57.2, 36.9, 30.6, 21.9.

endo-2-[Hydroxymethyl-(4-pyridinyl)]-7-azabicyclo[2.2.1]heptane (29c): To a

solution of ester 50c ( 75 mg, 0.25 mmol) in dry CH2Cl2 ( 2 mL) was added
trifluoroacetic acid ( 0.2 mL, 2.6 mmol) dropwise with stirring under nitrogen. The
mixture was stirred for 3 h at room temperature and rendered basic with saturated
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Na2CO3 ( 3 mL). The organic layer was separated, dried ( Na2SO4), and concentrated
under reduced pressure. The residue was purified by chromatography ( CH2Cl2 :
MeOH : NH4OH, 100 : 10 : 1 ) to give 29c as white solid ( 48 mg, 95% yield). mp.
1

H NMR ( 400 MHz, CDCl3 ) δ 8.55 ( 2 H, d, J = 8.0 Hz ), 7.27 ( 2 H, d, J = 7.2 Hz ),

4.47 ( 2 H, s ), 4.00 ( 1 H, m), 3.73 ( 1 H, t, J = 6.0 Hz ), 3.62 ( 1 H, t, J = 6.0 Hz ),
2.06 ( 2 H, m), 1.60 ( 2 H, m), 1.46 ( 1 H, m), 1.16 ( 1 H, dd, J = 4.4 Hz).

General Procedure for the Preparation of Oxalate Salts. The free base compound

(50 mg) was dissolved in ether or THF (1-2 mL). This solution was added dropwise to
a solution of the oxalic acid (2.4 eq.) in ether (1-2 mL). The oxalate salts precipitated
instantaneously with the mixing of the two solutions. The salt was rinsed with cold
anhydrous ether three times to afford the salt as an analytically pure crystalline solid.
Some analytical samples contained minute amounts of water despite drying (48 h
under vacuum).

endo-2-[Hydroxymethyl-(2-pyridinyl)]-7-azabicyclo[2.2.1]heptane oxalate

(51a):

White solid, mp 96-98oC. Anal. Calc. for C12H16N2O·2(COOH)2: C, 50.00%; H,
5.24%; N, 7.29%. Found: C, 49.53%, H, 5.52%, N, 7.48%
endo-2-[Hydroxymethyl-(3-pyridinyl)]-7-azabicyclo[2.2.1]heptane oxalate

(51b):

Light yellow solid, mp 130-132oC. Anal. Calc. for C12H16N2O • (COOH)2 • H2O: C,
53.78%; H, 6.45%; N, 8.97%. Found: C, 53.19, H, 6.20%, N, 8.81%.
endo-2-[Hydroxymethyl-(4-pyridinyl)]-7-azabicyclo[2.2.1]heptane oxalate

(51c):
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Brown solid. Anal. Calc. for C12H16N2O·2(COOH)2: C, 50.00%; H, 5.24%; N, 7.29%.
Found: C, 50.47%, H, 5.65%, C, 7.79%.

Cyclohexene-4-carbonyl

chloride

(53):

To

a

stirred

solution

of

3-cyclohexene-1-carboxylic acid (98%, 5 g, 0.04 mol) was added a solution of thionyl
chloride ( 9 mL, 0.12 mol) dropwise in all-glass apparatus. The mixture was refluxed
for 3 h until no further bubbles were observed. The whole reaction mixture was then
stirred overnight at room temperature. The excess SOCl2 was carefully removed under
reduced pressure to provide the crude product 53, which could be further reacted
without purification. 1H NMR (400 MHz, CDCl3 ) δ 5.69( 2 H, m), 3.01 ( 1 H, m),
2.41 ( 2 H, m), 2.16 ( 3 H, m), 1.83 ( 1 H, m).

4-(N-Trifluoroacetylamino)cyclohexene (55): A solution of crude 53 (5.7 g, 0.04

mol) in CH2Cl2 ( 60 mL) containing tetrabutylammonium bromide ( 40 mg, 0.124
mmol) was cooled in an ice bath. A solution of sodium azide ( 3.1 g, 0.048 mol), in
water ( 10 mL) was added and the reaction mixture was stirred vigorously at 0oC for 2
h. The organic phase was separated, washed with water and dried with Na2SO4 for 20
h. Continued evolution of nitrogen as very small bubbles was observed during this
period. Trifluoroacetic acid ( 4.1 mL, 0.054 mol) was added dropwise to the filtered
solution which was thereafter refluxed for 6 h. The cooled reaction mixture was
washed with saturated aqueous sodium hydrogen carbonate solution, dried, and
concentrated. The crystalline residue is distilled in a Kugelrohr apparatus
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( bulb-to-bulb) at 90-100oC / 1 torr to give 55 ( 5 g, 65% from the starting reagent 52)
as a white crystalline solid. mp 60-63oC.

1

H NMR ( 400 MHz, CDCl3 ) δ 6.24 ( 1 H,

br s), 5.73 ( 1 H, m), 2.63 ( 1 H, m), 4.18 ( 1 H, m), 2.44 ( 1 H, d, J = 17.2 Hz ), 2.16
( 2 H, m), 1.93 ( 2 H, m), 1.72 ( 1 H, m).

4-(N-Methyl-N-trifluoracetylamino)cyclohexene (56): A stirred solution of 55 ( 9.7

g, 0.05 mol) and methyl iodide ( 10 mL, 0.16 mol) in dry DMF ( 60 mL) was cooled
in an ice bath. Sodium hydride ( 60% oil dispersion in mineral oil, 2.5 g, 0.06 mol)
was added in portions. The ice bath was removed, and stirring was continued at room
temperature for 1 h. The mixture was poured into water ( 400 mL) containing acetic
acid ( 5 mL) and extracted with ether. The organic phase was washed four times with
water, dried over sodium sulfate, filtered, and concentrated by distillation at normal
pressure on a steam bath. The residue was distilled at the aspirator through a short
Vigreux column to afford 56 ( 8.1 g, 78%) as light yellow oil.

1

H NMR ( 400 MHz,

CDCl3 ) δ 5.67 ( 2 H, m ), 4.26 ( 1 H, d), 4.62 ( 0.55 H, m), 4.05 (0.45 H, m), 3.00
( 1.65 H, s ), 2.93 ( 1.35 H, s), 2.15-2.25 ( 4 H, m), 1.75-1.82 ( 2 H, m).

4-(N-Methyl-N-trifluoracetylamino)-1,2-epoxy-cyclohexane (57): To a solution of
56 ( 10 g, 0.05 mol) in CH2Cl2 ( 200 mL), stirred in an ice bath, was added

m-chloroperoxybenzoic acid ( 70-75%, 12 g, 0.05 mol) in portions. After stirring for 4
h at room temperature, the excess peracid was destroyed by addition of aqueous
potassium iodide, followed by sodium sulfite. The organic phase was separated,
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washed three times with NaHCO3, and dried over Na2SO4. Filtration and evaporation
left crude oil 57 ( 10.6 g, 95%), which was further purified by kugelrohr distillation at
75-90oC (0.3 mm) to provide 57 ( 9.0 g, 81%) as a brown oil consisting of a mixture
of (66.7%) anti- and (33.3%) syn-isomers.

1

H NMR ( 400 MHz, CDCl3 ) δ 4.40

( 0.75 H, m), 3.79 ( 0.25 H, d, J = 7.2 Hz ), 3.20 ( 2 H, m), 2.93 ( 1.25 H, s), 2.86
( 0.75 H, s), 2.28 ( 1 H, m), 2.11 ( 1 H, m), 1.92 ( 2 H, m), 1.71 ( 1 H, m), 1.36 ( 1 H,
m).

Cis-4-(N-Methylamino)-1,2-epoxycyclohexane (58a): To a stirred solution of 57

( 6.4 g, 29 mmol) in methanol ( 18 mL) was added dropwise a solution of potassium
hydroxide ( 4.7 g, 34 mmol) in water ( 15 mL). After stirring at room temperature for
5 h, most of the methanol was removed under reduced pressure. The residue was
extracted with ether ( 3 × 30 mL) and dichloromethane ( 3 × 30 mL). The extract was
dried and concentrated to provide a single product 58a (2.66g, 75%) as an oil. 1H
NMR ( 400 MHz, CDCl3 ) δ 3.12 ( 1 H, d, J = 2.0 Hz ), 2.38 ( 3 H, s), 2.17 ( 2 H, m),
1.79 ( 1 H, m), 1.64 ( 1 H, dd), 1.51 ( 2 H, m), 1.29 ( 1 H, m).

exo-7-Methyl-7-azabicyclo[2.2.1]heptan-2-ol (59): A solution of 58a ( 2.2g, 17.3

mmol) and K2CO3 ( 69 mg, 0.5 mmol) in dry N-methylpyrrolidone (30 mL), was
heated under N2 atmosphere at 160oC in oil bath for 72 h. The dark mixture was
subjected to distillation under reduced pressure and then distillate was made slightly
acidic with HCl (conc.). The solvent was distilled and the residue was washed with
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hot ether to furnish 58a hydrochloride salt. The salt was dissolved in aqueous sodium
carbonate followed by continuous extraction with dichloromethane ( 24 h). the solvent
was then carefully removed under reduced pressure and the residue was purified by
column chromatography ( SiO2, CH2Cl2 : CH3OH : NH4OH, 100 : 10 :1 ) to afford 55
as a white solid ( 1.17 g, 55%). mp 46-47oC.

1

H NMR ( 400 MHz, CDCl3 ) δ 3.63

( 1 H, d, J = 7.2 Hz ), 3.20 ( 1 H, t, J = 3.6 Hz ), 3.11 ( 1 H, d, J = 4.0 Hz ), 2.78 ( 1 H,
br s), 2.25 ( 3 H, s), 1.68-1.77 ( 3 H, m), 1.52 ( 1 H, m), 1.12-1.20 ( 2 H, m).

2-Acetoxy-7-methyl-exo-7-azabicyclo[2.2.1]heptane ( 64 ) : To a stirred solution of

alcohol 59 ( 50 mg, 0.4 mmol ) in freshly distilled CHCl3 ( 3 mL ) under an
atmosphere of nitrogen was added dry pyridine ( 100 µL, 1.2 mmol ) and dry acetic
anhydride ( 110 µL, 1.2 mmol ). The solution was stirred at room temperature
overnight. The reaction was quenched with a saturated solution of NaHCO3 ( 5 mL )
and the organic layer was removed. The aqueous layer was washed with CHCl3 ( 3 ×
5 mL ) and the organic fractions were combined and concentrated. Purification was
achieved by flash chromatography ( SiO2, CH2Cl2 : MeOH : NH4OH, 90 : 10 : 1 ) to
yield 64 as a colorless oil ( 51 mg, 75% yield ). 1H NMR ( 400 MHz, CDCl3) δ 4.59
( 1 H, dd, J = 2.8, 4.4 Hz ), 2.28 ( 2 H, t, J = 4.8 Hz ), 2.28 ( 3 H, s ), 2.04 ( 3 H, s ),
1.70-1.83 ( 4 H, m ), 1.19-1.28 ( 2 H, m ).

13

C NMR ( 400 MHz, CDCl3 ) δ 171.2,

65.6, 60.3, 40.0, 34.6, 29,7, 24.8, 21.9, 21.4. Anal. Calcd for C11H17NO2•C2H2O4•H2O:
C, 47.60; H, 6.85; N, 5.04. Found: C, 47.39, H, 6.13; N, 4.57.
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2-Acetoxy-7-methyl-exo-7-azabicyclo[2.2.1]heptane methyliodide (65): To a stirred

solution of the ester 64 ( 34 mg, 0.2 mmol ) in dry THF ( 3 mL ) under an atmosphere
of nitrogen was added CH3I ( 1 mL ). The reaction was heated to reflux overnight to
give 65 as a light yellow solid ( 53 mg, 87% yield ). Anal. Calcd. For
C10H18NO2I•H2O: C, 36.45; H, 6.07; N, 4.25. Found: C, 36.60; H, 5.43; N, 3.98.
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